Chimeric Antigen Receptor T-Cell Therapy: What the Neuroradiologist Needs to Know

REFERENCES

1. 1.↵
   2. Sathyanarayanan V,
   3. Neelapu SS

   . Cancer immunotherapy: strategies for personalization and combinatorial approaches. Mol Oncol 2015;9:2043–53 doi:10.1016/j.molonc.2015.10.009 pmid:26548534

   CrossRefPubMed
2. 2.↵
   2. Khalil DN,
   3. Smith EL,
   4. Brentjens RJ, et al

   . The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol 2016;13:273–90 doi:10.1038/nrclinonc.2016.25 pmid:26977780

   CrossRefPubMed
3. 3.↵
   2. Ruella M,
   3. Xu J,
   4. Barrett DM, et al

   . Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med 2018;24:1499–1503 doi:10.1038/s41591-018-0201-9 pmid:30275568

   CrossRefPubMed
4. 4.↵
   U.S. Food and Drug Administration. STN: BL 125646/0. https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM574106.pdf. Accessed January 30, 2019.
5. 5.↵
   U.S. Food and Drug Administration. BL 125646/76. https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM606523.pdf. Accessed January 28, 2019.
6. 6.↵
   U.S. Food and Drug Administration. BL 125643/0 https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM581259.pdf. Accessed January 28, 2019.
7. 7.↵
   Chemical & Engineering News. Controlling CAR-T: How scientists plan to make the engineered T cell therapy safer, and work for more cancers. https://cen.acs.org/pharmaceuticals/oncology/Controlling-CAR-T-scientists-plan/96/i19. Accessed February 5, 2019.
8. 8.↵
   Leukemia and Lymphoma Society. Chimeric Antigen Receptor (CAR) T-Cell Therapy. https://www.lls.org/treatment/types-of-treatment/immunotherapy/chimeric-antigen-receptor-car-t-cell-therapy. Accessed February 6, 2019.
9. 9.↵
   National Cancer Institute. NCI Dictionary of Cancer Terms. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/car-t-cell-therapy. Accessed February 6, 2019.
10. 10.↵
    Dana Farber Cancer Institute. How CAR T-cell works. https://www.dana-farber.org/cellular-therapies-program/car-t-cell-therapy/how-car-t-cell-therapy-works/. Accessed February 6, 2019.
11. 11.↵
    2. Lee DW,
    3. Gardner R,
    4. Porter DL, et al

    . Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014;124:188–95 doi:10.1182/blood-2014-05-552729 pmid:24876563

    Abstract/FREE Full Text
12. 12.↵
    2. Neelapu SS,
    3. Tummala S,
    4. Kebriaei P, et al

    . Chimeric antigen receptor T-cell therapy: assessment and management of toxicities. Nat Rev Clin Oncol 2018;15:47–62 doi:10.1038/nrclinonc.2017.148 pmid:28925994

    CrossRefPubMed
13. 13.↵
    2. Santomasso BD,
    3. Park JH,
    4. Salloum D, et al

    . Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov 2018;8:958–71 doi:10.1158/2159-8290.cd-17-1319 pmid:29880584

    Abstract/FREE Full Text
14. 14.↵
    2. Gust J,
    3. Hay KA,
    4. Hanafi LA, et al

    . Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov 2017;7:1404–19 doi:10.1158/2159-8290.cd-17-0698 pmid:29025771

    Abstract/FREE Full Text
15. 15.↵
    MD Anderson Cancer Center. Chimeric Antigen Receptor (CAR) Cell Therapy Toxicity Assessment and Management—Adult. https://www.mdanderson.org/documents/for-physicians/algorithms/clinical-management/clin-management-cytokine-release-web-algorithm.pdf. Accessed February 18, 2019.
16. 16.↵
    2. Gofshteyn JS,
    3. Shaw PA,
    4. Teachey DT, et al

    . Neurotoxicity after CTL019 in a pediatric and young adult cohort. Ann Neurol 2018;84:537–46 doi:10.1002/ana.25315 pmid:30178481

    CrossRefPubMed
17. 17.↵
    2. Davila ML,
    3. Riviere I,
    4. Wang X, et al

    . Efficacy and toxicity management of 19–28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014;6:224ra25 doi:10.1126/scitranslmed.3008226 pmid:24553386

    Abstract/FREE Full Text
18. 18.↵
    2. Trauninger A,
    3. Leél-Ossy E,
    4. Kamson DO, et al

    . Risk factors of migraine-related brain white matter hyperintensities: an investigation of 186 patients. J Headache Pain 2011;12:97–103 doi:10.1007/s10194-011-0299-3 pmid:21331756

    CrossRefPubMed
19. 19.↵
    2. Smirniotopoulos JG,
    3. Murphy FM,
    4. Rushing EJ, et al

    . Patterns of contrast enhancement in the brain and meninges. Radiographics 2007;27:525–51 doi:10.1148/rg.272065155 pmid:17374867

    CrossRefPubMedWeb of Science
20. 20.↵
    2. Lin JK,
    3. Lerman BJ,
    4. Barnes JI, et al

    . Cost effectiveness of chimeric antigen receptor T-cell therapy in relapsed or refractory pediatric B-cell acute lymphoblastic leukemia. J Clin Oncol 2018 Sep 13. [Epub ahead of print] doi:10.1200/JCO.2018.79.0642 pmid:30212291

    CrossRefPubMed
21. 21.↵
    2. Hao Y,
    3. Eldjerou LK,
    4. Yang H, et al

    . Cost-effectiveness analysis of CTL019 for the treatment of pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia in the United States. In: Proceedings of the American Society of Hematology Annual Meeting and Exposition, Atlanta, Georgia. December 9–12, 2017; abstract 609
22. 22.↵
    2. Hernandez I,
    3. Prasad V,
    4. Gellad WF

    . Total costs of chimeric antigen receptor T-cell immunotherapy. JAMA Oncol 2018;4:994–96 doi:10.1001/jamaoncol.2018.0977 pmid:29710129

    CrossRefPubMed
23. 23.↵
    Managed Health Care Executive. CAR T-cell therapy life-saving treatment, huge price tag. https://www.managedhealthcareexecutive.com/sites/default/files/legacy/mm/digital/media/mhe1118_ezine_R1.pdf. Accessed February 6, 2019.
24. 24.↵
    Centers for Medicare & Medicaid Services. Proposed Decision Memo for Chimeric Antigen Receptor (CAR) T-cell Therapy for Cancers (CAG-00451N). Last Updated February 15, 2019. https://www.cms.gov/medicare-coverage-database/details/nca-proposed-decision-memo.aspx?NCAId=291. Accessed February 15, 2019.